Health Care Technology

Allscripts Healthcare (NASDAQ: MDRX) Reports EPS of $0.21 vs. $0.20 Estimate; Revenues $335.3M vs. $342.04M Estimate

J.P. Morgan Chase & Co. is lowering its price target on shares of MedAssets (NASDAQ: MDAS) to $18 from $20, and it has a Neutral rating on shares. In a note to investors, J.P. Morgan writes, "MDAS reported adjusted non-GAAP EPS of $0.17, $0.02 ahead of our estimate and $0.01 ahead of consensus...

Most Actives: F5 Networks, Inc. (FFIV) a provider of technology that optimizes the delivery of network-based applications and the security, performance and availability of servers, data storage devices and other network resources is trading at a price of $99.72, a dramatic change of -0.83 (-0.83...

Piper Jaffray has an Underweight rating and a $15 price target on shares of MedAssets, Inc. (NASDAQ: MDAS) after it reported earnings. In a note to investors, Piper Jaffray writes, "We believe there remains room for improvement at MDAS. Reported numbers were mostly in-line, but higher purchase...

JP Morgan has lowered the price target on MedAssets (NASDAQ: MDAS) from $20 to $18 and maintains its Neutral rating.

Oppenheimer & Co. has a Outperform rating and a $21 price target on shares of MedAssets (NASDAQ: MDAS) following earnings. In a note to investors, Oppenheimer writes, "MedAssets delivered a modest beat in 1Q11, albeit on fairly low expectations. The company's spend management unit continues to...

SXC Health Soultions (NASDAQ: SXCI) Reports EPS of $0.33 vs. $0.34 Estimate; Revenues $1.1B vs. $809.75M Estimate

MedAssets (NASDAQ: MDAS) Reports EPS of $0.17 vs. $0.16 Estimate; Revenues $136.1M vs. $134.76M Estimate

TRANSCEND SERVICES,(NASDAQ: TRCR), a leading provider of clinical documentation services to the U.S. healthcare market, announced today that it has closed its previously announced acquisition of Nashville, Tennessee-based DTS America, Inc., effective April 30, 2011. Founded in 1995, DTS is a...

Piper Jaffray maintained its Overweight rating on Omnicell (NASDAQ: OMCL) in a research report published today. It also left its price target unchanged at $17. In the report, Piper Jaffray states, "The company reported a penny upside on EPS and in-line revenues by continued expansion in gross...

Omnicell (NASDAQ: OMCL) Reports EPS of $0.11 vs. $0.10 Estimate; Revenues $57.2M vs. $57.72M Estimate

According to J.P. Morgan, Cerner (NASDAQ: CERN) put up a solid 1Q, with bookings up 30% y/y to $525M, $70M ahead of expectation. J.P. Morgan said that EPS of $0.80 was $0.04 ahead of estimate and $0.03 ahead of Bloomberg consensus, with $0.02 of the upside coming from a lower tax rate. “The strong...

According to Deutsche Bank, Cerner (NASDAQ: CERN) kicks off FY11 with stellar results, highlighted by huge bookings beat. Deutsche Bank said that top and bottom-line beats with bookings coming in well above DB estimates. “System sales were up +20%, with international markets showing signs of...

Deutsche Bank has raised the price target on Cerner (NASDAQ: CERN) from $107 to $116 and maintains its Hold rating.

JP Morgan has raised the price target on Cerner (NASDAQ: CERN) from $115 to $120 and maintains its Overweight rating.